“Selective Inhibition of Tyrosine Kinase 2 With Deucravacitinib (BMS-986165) Compared With Janus Kinase 1−3 Inhibitors”. SKIN The Journal of Cutaneous Medicine 4, no. 6 (October 27, 2020): s108. Accessed May 22, 2025. https://skin.dermsquared.com/skin/article/view/1081.